DAPT guided by platelet function tests or genotyping after PCI: pros and cons

EuroIntervention 2023;19:546-548. DOI: 10.4244/EIJ-E-23-00022

Dominick Angiolillo
Dominick J. Angiolillo1, MD, PhD; Mattia Galli2, MD, PhD; Antonio Landi3,4, MD; Marco Valgimigli3,4, MD, PhD
1. Division of Cardiology, University of Florida College of Medicine - Jacksonville, Jacksonville, FL, USA; 2. Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy; 3. Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland; 4. Department of Biomedical Sciences, University of Italian Switzerland, Lugano, Switzerland
Introduction The importance of personalised medicine has been increasingly recognised over the last decade, with promises of optimising outcomes and minimising the risk of adverse events. This is also the case when dealing with tools to guide the selection and duration of dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention (PCI), including platelet function testing and genotyping. Guided DAPT has not been routinely adopted in clinical practice due to costs, logistical challenges, and conflicting evidence. While these approaches have shown promise in reducing the risk of adverse cardiovascular events, their clinical utility and cost-effectiveness remain to be established.##...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Cerebral embolic protection during transcatheter heart interventions

Latest news